Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Bayesian Adaptive Dose Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Intravenous Infusions GSK315234A in Patients With Active Rheumatoid Arthritis (RA).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 315234 (Primary) ; GSK 315234 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 30 Mar 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 30 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Aug 2007 to Apr 2008 as reported by Clinicaltrials.gov